Mannstadt, Michael
Bilezikian, John P.
Thakker, Rajesh V.
Hannan, Fadil M.
Clarke, Bart L.
Rejnmark, Lars
Mitchell, Deborah M.
Vokes, Tamara J.
Winer, Karen K.
Shoback, Dolores M.
Article History
First Online: 31 August 2017
Competing interests
: M.M. has received consulting fees and a research grant from Shire Pharmaceuticals. J.P.B. is a consultant for Shire Pharmaceuticals. R.V.T. has received grant funding from NPS/Shire Pharmaceuticals, GlaxoSmithKline, Novartis Pharma AG and the Marshall Smith Syndrome Foundation, and he is a medical adviser for the patient charity HypoPara UK. F.M.H. has received grant funding from NPS/Shire Pharmaceuticals and GlaxoSmithKline. B.L.C. has received research grants from Shire Pharmaceuticals and has received honoraria from Amgen. L.R. has received honoraria and speaker fees from Amgen, Eli Lilly, Novo Nordic, Takeda Pharmaceuticals, NPS Pharmaceuticals, Shire, Bristol-Myers Squibb, Abbott, and Boehringer Ingelheim Denmark. T.J.V. is a consultant and investigator for Shire Pharmaceuticals. D.M.S. is a consultant for Shire Pharmaceuticals and Ascendis Pharmaceuticals. D.M.M. and K.K.W. declare no competing interests.